Depressive Disorder, Treatment-Resistant clinical trials

The registry lists 448 studies for Depressive Disorder, Treatment-Resistant across more than 10 countries. 147 are recruiting or about to start. 301 of them are mainly about Depressive Disorder, Treatment-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Depressive Disorder, Treatment-Resistant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 178
Recruiting: 114
Status unknown: 38
Active, not recruiting: 30
Not yet recruiting: 26
Terminated: 25

Phase

Phase 2: 93
Phase 3: 46
Phase 4: 34
Phase 1: 33
Early Phase 1: 5

Where

United States: 204
Canada: 76
China: 30
Germany: 28
United Kingdom: 26
France: 23

Who runs them

Janssen Research & Development, LLC (16) · Centre for Addiction and Mental Health (15) · Stanford University (13) · Washington University School of Medicine (12) · Massachusetts General Hospital (11) · Changping Laboratory (8) · Sunnybrook Health Sciences Centre (8) · University of California, San Diego (7)

What is being tested here

Drugs under test in Depressive Disorder, Treatment-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Psilocybin	9	3	25
Ketamine	8	8	42
Esketamine	4	11	18
Nitrous Oxide	2	1	7
Aripiprazole	1	1	6
Risperidone	1	0	4
Bupropion	1	0	3
BPL-003	1	0	2
Pramipexole	1	0	2
Desethyloxybutynin	1	1	1

Drug classes tested here Serotonin receptor agonists 9 open · Antipsychotics 2 open · Inhaled anesthetics 2 open · SSRIs 1 open

Coming up

16phase 3 studies under way

55studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Feb 2027Sustained Mood Improvement With Laughing Gas Exposure · Phase 3 · Women's College Hospital
Apr 2027Biomarker-guided rTMS for Treatment Resistant Depression · Phase 3 · Weill Medical College of Cornell University
Nov 2026An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression · Beckley Psytech Limited
Nov 2026Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance · Motif Neurotech, Inc.
Nov 2026Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression · Ataturk University
Nov 2026Compressed Intermittent Theta Burst Stimulation · University of Pennsylvania
Nov 2026Maintenance rTMS for Depression (Maitr-De) · University of California, San Diego
Dec 2026Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: · Mayo Clinic
Dec 2026EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT · Istanbul University - Cerrahpasa
Dec 2026EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT · Istanbul University - Cerrahpasa

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger. 1 (1%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 13 (11%) take healthy volunteers.

Recruiting studies that take each age, of 114
Age	Women	Men
10	0 (0%)	0 (0%)
18	94 (82%)	94 (82%)
30	108 (95%)	108 (95%)
40	108 (95%)	108 (95%)
50	107 (94%)	107 (94%)
65	105 (92%)	105 (92%)
75	48 (42%)	48 (42%)
85	34 (30%)	34 (30%)

Across all 448 studies, recruiting or not: 66% stop at 75 or younger and 45% at 65; 3% take children; 1% are for women only and <1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Depressive Disorder, Treatment-Resistant studies take

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	41 mo16–59 · 19 studies	—	—
Phase 2	31 mo17–41 · 50 studies	—	—
Phase 3	30 mo24–59 · 24 studies	—	—
Phase 4	38 mo27–59 · 18 studies	—	—
Interventional, no phase	50 mo22–88 · 140 studies	—	42 mo22–79 · 136 studies
Observational	52 mo31–65 · 32 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 448. Browse all 448 → or search them.